These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10187204)

  • 1. The distribution of health care costs and their statistical analysis for economic evaluation.
    Briggs A; Gray A
    J Health Serv Res Policy; 1998 Oct; 3(4):233-45. PubMed ID: 10187204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of health care costs and their statistical analysis for economic evaluation (Vol 3 No 4 pp 233-245).
    Thompson S; Barber J
    J Health Serv Res Policy; 1999 Oct; 4(4):255-6. PubMed ID: 10623043
    [No Abstract]   [Full Text] [Related]  

  • 3. Parametric modelling of cost data in medical studies.
    Nixon RM; Thompson SG
    Stat Med; 2004 Apr; 23(8):1311-31. PubMed ID: 15083485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
    O'Hagan A; Stevens JW
    Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At what price significance? The effect of price estimates on statistical inference in economic evaluation.
    Rittenhouse BE; Dulisse B; Stinnett AA
    Health Econ; 1999 May; 8(3):213-9. PubMed ID: 10348416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parametric modelling of cost data: some simulation evidence.
    Briggs A; Nixon R; Dixon S; Thompson S
    Health Econ; 2005 Apr; 14(4):421-8. PubMed ID: 15685641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey.
    Healey A; Knapp M; Marsden J; Gossop M; Stewart D
    J Health Serv Res Policy; 2003 Jul; 8(3):134-41. PubMed ID: 12869338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.
    Graves N; Walker D; Raine R; Hutchings A; Roberts JA
    Health Econ; 2002 Dec; 11(8):735-9. PubMed ID: 12457373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for testing equality of means of health care costs in a paired design study.
    Zhou XH; Li C; Gao S; Tierney WM
    Stat Med; 2001 Jun; 20(11):1703-20. PubMed ID: 11391697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.
    Kilian R; Matschinger H; Löeffler W; Roick C; Angermeyer MC
    J Ment Health Policy Econ; 2002 Mar; 5(1):21-31. PubMed ID: 12529567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for comparison of cost data.
    Zhou XH; Melfi CA; Hui SL
    Ann Intern Med; 1997 Oct; 127(8 Pt 2):752-6. PubMed ID: 9382393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A note on confidence intervals in cost-effectiveness analysis.
    Tambour M; Zethraeus N; Johannesson M
    Int J Technol Assess Health Care; 1998; 14(3):467-71. PubMed ID: 9780533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation and health care. What does it mean?
    Robinson R
    BMJ; 1993 Sep; 307(6905):670-3. PubMed ID: 8401057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian estimation of cost-effectiveness ratios from clinical trials.
    Heitjan DF; Moskowitz AJ; Whang W
    Health Econ; 1999 May; 8(3):191-201. PubMed ID: 10348414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical methods for cost-effectiveness analyses.
    Siegel C; Laska E; Meisner M
    Control Clin Trials; 1996 Oct; 17(5):387-406. PubMed ID: 8932972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition, interpretation and calculation of cost-effectiveness acceptability curves.
    Löthgren M; Zethraeus N
    Health Econ; 2000 Oct; 9(7):623-30. PubMed ID: 11103928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution.
    Jones AM; Lomas J; Rice N
    Health Econ; 2015 Sep; 24(9):1192-212. PubMed ID: 25929525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of osteoporosis prevention.
    Johannesson M; Jönsson B
    Health Policy; 1993 May; 24(2):103-24. PubMed ID: 10126753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.
    O'Brien BJ; Drummond MF; Labelle RJ; Willan A
    Med Care; 1994 Feb; 32(2):150-63. PubMed ID: 8302107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.